A case series titled “Fenbendazole as an Anticancer Agent? A Case Series of Self-Administration in Three Patients,” published in the peer-reviewed journal Case Reports in Oncology in 2025 (DOI 10.1159/000546362, PMID 40605964), described three patients with stage IV cancers (breast, prostate, and melanoma) who self-administered fenbendazole — an over-the-counter veterinary dewormer with no FDA approval for human use of any kind, let alone cancer treatment — alongside their standard treatments, and reported that all three went into remission. The article circulated widely online, including on social media, as purported evidence that a cheap, unregulated dewormer “cures cancer.” On January 21, 2026, the journal’s Editor, Dr. Maurie Markman, retracted the article (retraction statement: DOI 10.1159/000549387, PMID 41574240) after it came to light that the lead author had an undeclared financial conflict of interest — specifically, that he offers paid clinical services related to treating cancer patients with fenbendazole, a fact not disclosed in the article’s conflict-of-interest statement. The retraction notice is explicit that the concern is the undisclosed conflict of interest, not that the underlying case data was found to be fabricated or incorrect; the retraction nonetheless means the paper is no longer valid, citable evidence. No clinical trial has ever tested whether fenbendazole treats cancer in humans, and case reports of self-administered, uncontrolled treatment combinations of this kind cannot establish that fenbendazole caused these three patients’ outcomes, since all three were also receiving conventional cancer treatment at the same time.

The randomized, open-label, phase 3 ASCENT-07 trial (ClinicalTrials.gov NCT05840211) compared sacituzumab govitecan (Trodelvy), an antibody-drug conjugate already FDA-approved for other breast-cancer indications, against standard-of-care chemotherapy as a first chemotherapy option in 690 patients with hormone-receptor-positive, HER2-negative advanced breast cancer previously treated with endocrine therapy. Presented at the San Antonio Breast Cancer Symposium on 2025-12-10, the trial did NOT meet its primary endpoint of progression-free survival by blinded independent central review: after a median follow-up of 15.4 months, median progression-free survival was 8.3 months in BOTH arms (hazard ratio 0.85), meaning sacituzumab govitecan did not outperform standard chemotherapy in this specific setting. This is a genuinely negative result for this particular combination and patient population — it does not call into question sacituzumab govitecan’s existing FDA approvals for its OTHER, already-approved indications, which this record makes no claim about.

[SINGLE-PATIENT CASE REPORT — EXTREMELY LIMITED EARLY HUMAN EVIDENCE. This story is based on a published, peer-reviewed report of ONE human patient. It is NOT a clinical trial, and it does NOT establish that this treatment works for glioblastoma. The GIANT Phase II trial is a separate, subsequent study designed to test that question — its results are not yet available and are not part of this evidence. This is the weakest tier of actual human evidence CancerDiscoveries classifies (stronger than laboratory/animal-only research, far weaker than a clinical trial). This disclosure does not state or imply that a physician reviewed this specific case.]

A published case report of neoadjuvant checkpoint immunotherapy in glioblastoma has led to a follow-on Phase II trial. Primary publication (case report — reports ONE patient): PMID 40016450, https://pubmed.ncbi.nlm.nih.gov/40016450/, DOI https://doi.org/10.1038/s41591-025-03512-1. Follow-on trial: GIANT, https://clinicaltrials.gov/study/NCT06816927, Phase II/recruiting as of the current source record. CRITICAL: the primary publication is a single-patient case report and does NOT establish treatment efficacy — the Phase II study is the appropriate next evidence stage, and any summary of this story must prominently state the one-patient limitation, not bury it. [Identifiers as supplied, attributed to independent verification outside this environment — not independently re-verified live here.]